Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV

Open source

DOI: 10.1016/j.ejca.2025.115381
Published: 2025 May 2
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115381,
  title = {Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.},
  author = {Luke JJ and Ascierto PA and Khattak MA and Rutkowski P and Del Vecchio M and Spagnolo F and Mackiewicz J and Merino LC and Chiarion-Sileni V and Kirkwood JM and Robert C and Schadendorf D and de Galitiis F and Carlino MS and Dummer R and Mohr P and Odeleye-Ajakaye A and Fukunaga-Kalabis M and Krepler C and Eggermont AMM and Long GV},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.115381},
  url = {https://doi.org/10.1016/j.ejca.2025.115381}
}

RIS

TY  - JOUR
TI  - Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
AU  - Luke JJ
AU  - Ascierto PA
AU  - Khattak MA
AU  - Rutkowski P
AU  - Del Vecchio M
AU  - Spagnolo F
AU  - Mackiewicz J
AU  - Merino LC
AU  - Chiarion-Sileni V
AU  - Kirkwood JM
AU  - Robert C
AU  - Schadendorf D
AU  - de Galitiis F
AU  - Carlino MS
AU  - Dummer R
AU  - Mohr P
AU  - Odeleye-Ajakaye A
AU  - Fukunaga-Kalabis M
AU  - Krepler C
AU  - Eggermont AMM
AU  - Long GV
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.115381
UR  - https://doi.org/10.1016/j.ejca.2025.115381
ER  -

APA

JJ, L., PA, A., MA, K., P, R., M, D. V., F, S., J, M., LC, M., V, C., JM, K., C, R., D, S., F, D. G., MS, C., R, D., P, M., A, O., M, F., C, K., AMM, E., & GV, L. (2025). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115381

Source records

pubmed · retrieved 2026-09-26T06:20:52.249Z